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Psoriatic arthritis (PsA) is a chronic inflammatory condition 
associated with skin psoriasis and manifests a wide clinical 
phenotype, with proposed differences between sexes. Current 
treatments are based on traditional disease-modifying anti-
rheumatic drugs (DMARD), and biologic agents and studies 
have reported different clinical response patterns depending 
on sex factors. We aimed to identify sex differences in drug 
retention rate in patients with PsA and performed a systematic 
research on MEDLINE, EMBASE and Cochrane databases (1979 
to June 2015) for studies regarding effectiveness (measured 
as drug retention rate) in PsA in both traditional DMARDs 
and biologics. Demographic data as well as retention rates 
between sexes were extracted. From a total 709 retrieved 
references, we included 9 articles for the final analysis. Only 
one study reported data regarding DMARDs, while eight studies 
reported retention rate for anti-tumor necrosis factor (TNF) 
biologics, mainly infliximab, adalimumab and etanercept. No 
differences were reported in retention rates between sexes for 
methotrexate, while women manifested lower retention rates 
compared to men with regard to anti-TNF. We highlight the 
need to include sex differences in the management flow chart 
of patients with PsA.
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ABSTRACT:
KEY WORDS:
P soriatic arthritis (PsA) is a chronic systemic inflammatory disease that typically involves the synovial tissue, the enthe-
ses and the spine, in association with current psoriasis or a per-
sonal or family history of the skin condition. PsA belongs to the 
broader group of spondyloarthritides (SpA) which also include 
ankylosing spondylitis (AS), reactive arthritis, enteropathic 
arthritis, and undifferentiated spondyloarthritis [1]. These 
diseases share a strong genetic background, as represented 
by the association of AS with the HLA-B*27 allele, but unlike 
other rheumatic diseases there is no female preponderance or 
association with specific autoantibodies.
Recently, gender medicine has been receiving growing 
attention, namely, the study of how diseases differ between 
men and women in terms of diagnosis, clinical manifesta-
tions and therapeutic approach, with obvious implications for 
reproductive health. More importantly, research is moving to 
personalized medicine, a process that suggests the custom-
ization of health care tailored to every patient. Personalized 
medicine not only takes into account the sex of the patient, 
but may investigate his/her DNA for pharmacogenomics to 
tailor the individual most appropriate therapy for better cost-
effectiveness. Nonetheless and different from rheumatoid 
arthritis, few studies have investigated the role of sex in the 
development of psoriatic disease, especially PsA.
PsA clinical manifestations vary widely to include peripheral 
arthritis, axial involvement, enthesitis and dactylitis. Earlier 
reports suggested that spondyloarthritides were predominant 
in men [2], but PsA is currently considered a disease equally 
affecting both sexes [3], with studies alternatively reporting 
male [4] or female [5] preponderance. Sex differences in PsA 
include a more frequent axial involvement in men [6] and a 
predominant peripheral arthritis with higher disability scores in 
women [7]. However, few studies have assessed the differences 
in clinical manifestations between sexes, especially in large 
cohorts of patients. 
The treatment of PsA has been discussed in recent guide-
lines and recommendations and is based on non-steroidal anti-
inflammatory drugs (NSAIDs), traditional disease-modifying 
anti-rheumatic drugs (DMARDs), particularly methotrexate 
(MTX), biologic agents blocking tumor necrosis factor-alpha 
(TNFα), interleukin (IL)-12/IL-23, IL-17, and most recently 
small molecules directed at phosphodiesterase-4 (anti-PDE4), 
which represent target therapies for key molecules involved in 
psoriatic disease pathogenesis [8-12]. Sex differences are seen 
in the outcomes of PsA treatment options, including anti-
inflammatory drugs and anti-TNFα which are prescribed more 
frequently in men with PsA, while discrepancies have been 
reported in the prescription of DMARDs, especially MTX and 
sulfasalazine, in men and women. Furthermore, drug retention 
rates, which measure the overall benefit of a treatment (effective-
ness) being the result of both positive (persistent efficacy) and 
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negative (loss of efficacy and adverse events) treatment effects, 
as well as a series of medical and non-medical factors (those not 
primarily related to the treatment effect) that influence drug use, 
are reported to be different between the sexes. These are gener-
ally longer in men [13], with women having better treatment 
response and a better prognosis, with lower rates of radiographic 
progression and lower values of the different scoring systems 
used in the evaluation of PsA and other SpA [14]. 
We performed a systematic literature review to investigate 
the role of sex in the use and retention rate of different con-
ventional and biologic treatments in patients with PsA, and 
we propose our stance on this issue.
METhODS FOR ThE SYSTEMATIC lITERATuRE REVIEW
Our literature review was conducted to identify sex differences 
in drug retention rates in PsA patients treated with conventional 
DMARDs and biologic agents. The systematic review proce-
dures we used conform to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines. 
Structured literature searches were conducted in June 2015 
in the following databases: the Cochrane Library, PubMed/
MEDLINE and EMBASE. Search terms included those for the 
disease, using the following medical subject headings (MeSH) 
and Emtree terms: psoriatic arthritis, treatment, and retention 
rate. Titles and abstracts were screened to determine if they met 
the inclusion criteria and, if potentially relevant, two indepen-
dent reviewers selected relevant abstracts.
Included in the review were clinical trials, both interven-
tional and observational, of patients with PsA. 
Excluded were articles not concerning PsA, and reviews or 
editorials, in languages other than English, that involved chil-
dren or animals. The selection process was performed by two 
authors, based on titles, abstracts and subsequently on full 
text papers. Figure 1 represents the flowchart of the selection 
process of this systematic literature review. Our outcome was 
drug retention rate. The full text analysis excluded 23 papers 
and the final analysis was performed on 9 full text papers. 
With regard to data extraction, the year of publication, 
geographic area, study design and number of patients were 
recorded. Demographic data, such as sex, age and disease 
duration were also recorded. The outcome was defined by the 
presence of retention rates classified by sex. The quality of pub-
lications was determined by use of the Newcastle Ottawa Scale 
(NOS).
RESulTS OF ThE SYSTEMATIC lITERATuRE REVIEW
A total of 709 articles were identified, of which 662 were 
excluded because they were not relevant, were duplicates, or 
used a language other than English. On reapplying the inclusion 
criteria, 32 articles were selected for full text analysis, result-
ing in 9 full text papers [15-23] for a total of 4380 patients. All 
articles were observational studies. The demographic features of 
subjects included in the studies are presented in Table 1.
The different treatments regarding retention rates and arthri-
tis co-medications are listed in Table 2. The great majority of the 
included studies (8/9) investigated the retention rate of anti-
TNFα agents (infliximab, adalimumab and etanercept), while 
only one study investigated MTX. The quality was assessed by 
the use of NOS, the grades ranged from * (1) to ***** (5) mean 
4.2 (standard deviation SD ± 0.97). 
Table 1. Demographic characteristics of the population included in the studies
Study Year
Geographic 
area
Total 
patients, n
Female,  
n (%) Age, years 
Disease 
duration, 
years 
Fabbroni et 
al. [15]
2014 Italy 268* 126 (47) Median 52  
(IQR 44-61.5)
Mean 8.2  
(7.2)
Fagerli et al. 
[16]
2014 Norway 440 204 (46.4) Mean 46.5  
(SD 11.6)
Median 5.2 
(1.5-12.5)
Glintborg et 
al. [17]
2011 Denmark 764 396 (52) Median 47  
(IQR 38-56)
Median 5  
(2-11)
Glintborg et 
al. [18]
2013 Denmark 1422 699 (49) Median 48  
(IQR 38-56)
Median 4  
(1-10)
Gomez-Reino 
et al. [19]
2006 Spain 470 – – –
Heiberg et al. 
[20]
2008 Norway 172 63 (36.6) Mean 45.7  
(SD 10.8)
Mean 12.1  
(SD 9.3)
Kristensen et 
al. [21]
2008 Sweden 261 128 (49) Mean 47  
(SD -)
–
Lie et al. [22] 2010 Norway 430 200 (46.5) Mean 49.2  
(SD 2.9)
Mean 4.4  
(SD 6.6)
Mok et al. [23] 2014 Hong Kong 153 – – Mean 7.9  
(SD 6.4)
*Including also patients with ankylosing spondylitis and axial spondyloarthritis
Figure 1. Flow chart for management of patients with suspected pancreatic injury
Records identified through database searching (709)
Records identified after duplicates removed (690)
Records screened (690)
9 articles included
n=4380
Full text articles excluded (with reasons) (23)
Review (5)
Wrong outcome (9)
Wrong exposure (7)
Letter (1)
Language other than English (1)
Records 
excluded 
(662)
Full text articles 
assessed for 
eligibility (32)
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first to subsequent treatment lines. The results reported that 
men manifested a longer drug survival of the second biologic 
agent, compared to women (P = 0.02). 
Gomez-Reino et al. [19] performed an observational study 
on more than 4000 patients with chronic arthritis from the 
BIOBADASER registry of Spain; 10% had a diagnosis of PsA. 
In the entire cohort investigated there were 5263 treatment 
courses and 1221 discontinuations. Even if the differences 
between the sexes in the subpopulations were not reported, 
the authors suggested that female sex is not an independent 
predictor of discontinuation (HR 1.25, 95%CI 1.10–1.43). 
Heiberg and team [20] investigated the 1 year survival rates 
of three different anti-TNF biologic agents in rheumatoid 
arthritis (RA), PsA and SpA. The crude 1 year survival rate in 
PsA was 77.3%. Independently of the diagnosis, women were 
associated with a higher risk of treatment discontinuation (HR 
1.51, 95%CI 1.19–1.93). Kristensen et al. [21] reported no dif-
ferences between sexes in drug survival in PsA patients treated 
with anti-TNFα. 
Only one study, by Lie et al. [22], reported the retention 
rate of MTX in PsA patients. MTX was discontinued in about 
17% of the patients in the first 6 months of therapy, mainly for 
adverse events. Interestingly, no differences between sexes in 
the discontinuation rate of MTX were identified, as men were 
associated with an HR of 1.06 (95%CI 0.89–1.27). At 12 months 
24% of PsA patients had discontinued MTX. 
Mok and co-authors [23] compared the retention rates of 
different biologics used for the treatment of rheumatic diseases 
and found that women had an increased risk of anti-TNF dis-
continuation (HR 1.46, 95%CI 1.18–1.81). 
ThE CuRREnT OuTlOOK
Gender medicine represents an avant garde branch of medicine, 
focusing on differences between women and men in health 
and disease. Semantics show that gender differs from sex, 
with the latter meaning the biology along with the anatomic 
Fabbroni et al. [15] performed a retrospective and obser-
vational analysis of SpA patients treated with anti-TNF (213 
diagnosed with PsA), for a total of 353 treatment courses of 
which 98 were interrupted, with no differences between the three 
biologic agents. Women manifested a shorter treatment duration 
compared to men, mean 20.1 months (SD ± 20.1) and 31.2 (SD 
± 24.5) respectively. Women were also associated with a higher 
risk of treatment discontinuation, corresponding to an odds ratio 
(OR) of 2.227, 95% confidence interval (95%CI) 1.335–3.716. 
Fagerli and colleagues [16] investigated the role of MTX co-
medication in patients with PsA treated with anti-TNF. Female 
sex was identified as a predictor of treatment termination after 
3 years in their cohort, but it did not reach statistical signifi-
cance: hazard ratio (HR) 1.17, 95%CI 0.83–1.64. 
Glintborg et al. [17] in 2011 reported the anti-TNF response 
and drug survival in 764 PsA patients derived from the DANBIO 
registry, for a total treatment period of 2135 person-years. In 
this cohort, 336 patients discontinued their treatment, mainly 
for lack of efficacy. The median drug survival was 2.9 years, with 
1 and 2 year drug retention rates of 70 and 57% respectively. Sex 
differences were reported in retention rates for all the biologic 
agents included, with men manifesting a longer drug survival 
compared to women (P > 0.001). Interestingly, MTX use at base-
line did not affect drug survival. In a subsequent analysis, female 
sex was confirmed to be associated with a shorter drug survival 
and was identified as a predictor (HR 1.8, 95%CI 1.3–1.9). The 
authors also reported other sex differences, both in baseline 
characteristics and clinical response. With regard to the former, 
women at baseline had significantly higher HAQ sores, Visual 
Analogue Scale (VAS) scores and tender joints, while mani-
festing lower scores for swollen joints. However, age, disease 
duration, DAS28 scores and baseline C-reactive protein (CRP) 
levels were not statistically different between sexes. Finally, men 
were associated with a better clinical response (OR 1.5, 95%CI 
1.5–3.2). Furthermore, Glintborg et al. [18] in 2013 investigated 
whether sex influences drug survival after switching from the 
Table 2. Treatments investigated and arthritis co-medications
Study MTx n (%) Treatment Major observations
Fabbroni et al. [15] 44 (16.4) IFX, ADA, ETN Women have a shorter treatment duration, and a higher risk of treatment discontinuation
Fagerli et al. [16] 270 (61.3) IFX, ADA, ETN Women have a higher risk of treatment termination after 3 years, not statistically significant
Glintborg et al. [17] 410 (54) IFX, ADA, ETN Women have lower drug retention rates at 1 and 2 years; MTX does not affect drug survival 
Glintborg et al. [18] 765 (53.8) IFX, ADA, ETN Women have lower drug survival after switching to the 2nd biologic agent
Gomez-Reino et al. [19] – IFX, ADA, ETN Female sex is not associated with discontinuation
Heiberg et al. [20] 117 (68) IFX, ADA, ETN Women have a higher risk of discontinuation
Kristensen et al. [21] 161 (61.6) IFX, ADA, ETN No differences
Lie et al. [22] 430 (100) MTX No differences
Mok et al. [23] – IFX, ADA, ETN Women have higher discontinuation rates
IFX = infliximab, ADA = adalimumab, ETN = etanercept, MTX = methotrexate 
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ies. Our systematic review of the literature supports the view 
that women manifest a shorter treatment duration with anti-
TNFα biologics compared to men [15,17,18,20]. Interestingly, 
only one study addressed the retention rate of MTX in PsA, 
reporting no differences between genders [22].
ThOuGhTS FOR ThE FuTuRE
The PsA research agenda is moving fast to identify new bio-
markers for disease early diagnosis, prognosis and stratifica-
tion, and gender medicine seems to be a major crossroad 
towards personalized medicine, even though it is commonly 
overlooked. Genetics, which represents is a major risk factor 
for psoriasis and PsA, with the former being associated mainly 
with HLA-Cw*06 [31] and the second with HLA-B*27 [7], 
may provide further help in choosing the most appropriate 
therapy, as patients carrying the HLA- Cw*06 allele seem to 
respond better to ustekinumab [31]. Women may also benefit 
more from this treatment since they are reported to carry the 
HLA-Cw*06 allele more frequently; in contrast, HLA-B*27 is 
more frequent in men. Twin studies in the future may help to 
dissect the role of genetics in the development of PsA, and also 
help in the identification of environmental risk factors, such as 
smoking or trauma [32]. Moreover, PsA has been associated 
also with the presence of anti-carbamylated protein (anti-CarP) 
antibodies, found also in RA, suggesting an autoimmune back-
ground of the disease [33] and possibly the opportunity for a 
specific diagnostic test for the disease.
Cardiovascular disease is an issue of major interest in PsA 
and we expect that the research agenda will move forward in 
the following years, as occurred in rheumatoid arthritis. Indeed, 
patients with psoriasis and PsA have a higher incidence and 
prevalence of myocardial infarction and stroke compared to 
the general population [34]. This increased risk seems to be 
due not only to traditional risk factors but also to chronic sys-
temic inflammation that may accelerate atherosclerosis [35]. 
Metabolic syndrome is also reported to be more frequent in 
PsA, thus increasing the cardiovascular risk burden and is 
associated with disease activity [35]. A screening tool has not 
yet been established and the existing ones may underestimate 
the real cardiovascular risk [36]; and since women and men 
have different risk profiles, gender should be taken into account 
when evaluating patients and choosing a therapy. We expect 
that in the future more targeted therapies will reduce this 
incremental burden of disease in PsA and thereby reduce mor-
bidity and mortality of patients as well as the risk of paradoxi-
cal adverse events [37]. We suggest more accurate and closer 
monitoring in men and women after menopause [38]. 
Finally, microbiome analysis has become the most increas-
ing area of interest in chronic inflammatory diseases. In the 
case of PsA, there is increased risk to develop Crohn disease 
and data on the intestinal microbiome show similar data for 
intestinal disease and psoriasis. However, few studies have 
reproductive system and secondary sex characteristics, while 
gender refers more to the social side or personal identification, 
and may thus differ from the biology. In general terms and in 
the literature, however, these terms are used as synonyms and 
encompass genetics and environmental factors. 
In autoimmune and rheumatic diseases, sex has histori-
cally been central, as most of these diseases more frequently 
affect women, with the most striking sex differences observed 
in Sjogren’s syndrome, systemic lupus erythematosus, primary 
biliary cirrhosis, autoimmune thyroid disease and systemic 
sclerosis, with women representing over 80% of patients [24]. 
Sex is thus associated with the development of several autoim-
mune diseases, since hormonal factors and sex chromosomes 
have been identified as possible pathogenetic factors inducing 
a sexual dimorphism in the immune system [25]. 
Few studies have investigated the role of gender in PsA, and 
results are variable. Some studies report a male predominance 
of the disease [4], while others suggest a more equal distribu-
tion between sexes [3]. Clinical manifestations also differ 
between men and women, with male patients more frequently 
having axial or oligoarticular involvement. Conversely, women 
manifest polyarticular features more frequently, but reports are 
inconsistent since some studies did not find differences between 
different clinical subsets [26]. With regard to disease severity, 
in different studies men are reported to develop more erosions 
and in general a more aggressive radiographic progression [27]. 
A striking difference is reported in patient-reported outcomes 
and quality of life: women seem to be more disabled in daily 
activities and have higher disability scores [27], perhaps due 
to a different pain perception, which has been reported also in 
osteoarthritis. Fatigue seems also to be higher in women [7,27], 
who report a higher fatigue severity score [27]. These observa-
tions on quality of life and fatigue have been reported also for 
other rheumatologic conditions, especially RA and AS. 
Co-morbidities are also an important issue in PsA and 
affect quality of life. Fibromyalgia is a major co-morbidity 
in PsA [28]. However, it may be difficult to assess the real 
disease activity in these patients due to a low correlation of 
joint count and biomarkers, i.e., CRP, and also because of the 
large overlap of enthesis and tender points [29].
As the clinical manifestations of PsA are variable, so are the 
treatment options different, ranging from traditional DMARDs 
for peripheral arthritis to biologics targeting TNFα or other 
pro-inflammatory cytokines for severe disease or disease with 
axial involvement. The use of traditional DMARDs is reported 
similarly in both sexes [30], with prescriptions more likely in 
women [27], even if we suggest that sexual factors, i.e., preg-
nancy, may affect the prescription of such drugs in young 
women. Biologics conversely seem to be more prescribed in 
men [30], perhaps due to higher axial involvement in males. 
Retention rate is an indirect measurement of treatment effi-
cacy and is currently used as an efficacy outcome in many stud-
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investigated skin and gut microbiome in patients with PsA or 
other SpA, with no focus on gender. Firmicutes, a major phylum 
of gut commensals, and especially the species Faecalibacterium 
prausnitzii and Clostridium leptum, are decreased in number, 
with a similar pattern seen in inflammatory bowel disease. 
These findings could establish a pathogenic link between gut 
inflammation and SpA. Moreover, the gut microbiome in PsA 
and psoriasis is decreased in number and diversity, similar to 
inflammatory bowel disease, as reported in a recent study [39]. 
These findings could help the future development of bacterial 
therapies that may replace the sick microbiome and reestablish 
a balance between microorganisms and the host, as observed 
in C. difficile infection. If the gut represents the ideal environ-
ment for microbiome development, the skin is less hospitable 
since microorganisms are more exposed to external agents and 
have fewer nutrients [40]. Some studies have investigated the 
composition of microbiome of the skin in psoriasis, showing 
the higher frequency of beta-hemolytic streptococcal infection 
and an abundance of Propionibacterium in psoriatic plaques. 
However, their interaction with the immune response is not yet 
clear, but a tolerance breakdown is suspected [40]. We expect 
that topical therapies will be developed in the next few years, as 
well as in other skin conditions, i.e., acne and rosacea. 
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Cystic fibrosis (CF) is caused by mutations in the gene that 
encodes the cystic fibrosis transmembrane conductance 
regulator (CFTR) anion channel. In humans and pigs, the loss 
of CFTR impairs respiratory host defenses, causing airway 
infection. But CF mice are spared. Shah et al. found that in all 
three species, CFTR secreted bicarbonate into airway surface 
liquid. In humans and pigs lacking CFTR, unchecked H+ 
secretion by the non-gastric H+/K+adenosine triphosphatase 
(ATP12A) acidified airway surface liquid, which impaired 
airway host defenses. In contrast, mouse airways expressed 
little ATP12A and secreted minimal H+; consequently, airway 
surface liquid in CF and non-CF mice had similar pH. Inhibiting 
ATP12A reversed host defense abnormalities in human and 
pig airways. Conversely, expressing ATP12A in CF mouse 
airways acidified airway surface liquid, impaired defenses, 
and increased airway bacteria. These findings help explain 
why CF mice are protected from infection and nominate 
ATP12A as a potential therapeutic target for CF.
Science 2016; 351: 503
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Capsule
Airway infections put to an acid test
B cells make antibodies through a process of somatic recom- 
bination. This gives rise to a diverse repertoire of antibodies 
able to target many pathogens, such as the malaria-causing 
parasite Plasmodium falciparum. Tan and collaborators 
screened the plasma of P. falciparum – in infected individuals 
to look for antibodies that kill infected red blood cells (RBCs). 
They isolated several monoclonal antibodies from multiple 
individuals that showed broad reactivity for infected RBCs. 
To their surprise, these antibodies all contained a genomic 
insertion that encoded a collagen-binding protein called LAIR1, 
and it was this insert, rather than the antibody-encoding gene 
segments themselves, which recognized the infected RBCs. 
Whether such insertions exist in other antibodies remains to 
be determined. 
Nature 2016; 529: 105
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Capsule
unusual antibodies target malaria
Liters of air pass through the lung every minute. Signals in 
the atmospheric environment are processed into physiolo- 
gical outputs, including the immune response. Branchfield 
and colleagues show that rare airway cells called pulmon- 
ary neuroendocrine cells (PNECs) sense and respond to 
airborne cues. Inactivating Roundabout genes in mouse 
PNECs prevent normal PNEC clustering and cause an in- 
crease in the production of neuropeptides, which in turn 
trigger a heightened immune response. Thus PNECs, 
despite their rarity, are sensitive and effective rheostats 
on the airway wall that receive, interpret, and respond to 
environmental stimuli. 
Science 2016; 351: 707
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neuroendocrine cells as air sensors
